Trade Mark Journal No.2026/007 13 February 2026

UK00004331564 28 January 2026 (5,10,44)

MANNKIND INHALE MY INSULIN

International priority date claimed: 27 January 2026 (European Union Intellectual Property Office (EUIPO)) (019309128)

Class 5: Pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, and metabolic diseases and disorders; Pharmaceutical preparations for treating diabetes; Inhalers filled with pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders.
Class 10: Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Instruments and apparatus provided empty used for the inhalation of pharmaceuticals; Inhalers for medical purposes, sold empty; Inhalers for therapeutic purposes, sold empty.
Class 44: Providing medical information in the field of treating metabolic and endocrine diseases and disorders, namely, diabetes; Medical and pharmaceutical consultation; Providing medical information in the field of health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing medical information, consultancy and advisory services; Providing medical information via a website; Providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users.

MannKind Corporation

Representative: Edwin Coe LLP